Ray Therapeutics closed a $125 million Series B financing to fund late-stage development and commercialization readiness for its lead optogenetic gene therapy RTx-015 in retinitis pigmentosa. Paul Bresge, the company’s CEO and cofounder, said the round supports an upcoming registrational Phase II/III study. RTx-015 is described as mutation-agnostic: by delivering bioengineered light-sensitive proteins into targeted retinal cells, the program aims to improve visual function regardless of the underlying genetic mutation. The company highlighted that retinitis pigmentosa remains progressive and has no approved therapies that restore lost vision. The financing underscores continued investor appetite for vision-restoration gene therapy platforms, particularly those designed to broaden the addressable patient population.